Buchumschlag

Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer

Estrogen receptor (ER) positive breast cancer is often effectively treated with drugs that inhibit ER signaling, i.e., tamoxifen (TAM) and aromatase inhibitors (AIs). However, 30% of ER+ breast cancer patients develop resistance to therapy leading to tumour recurrence. Changes in the methylation pro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Soleimani Dodaran, Maryam (Verfasst von) , Borgoni, Simone (Verfasst von) , Sofyali, Emre (Verfasst von) , Verschure, Pernette J. (Verfasst von) , Wiemann, Stefan (Verfasst von) , Moerland, Perry D. (Verfasst von) , van Kampen, Antoine H. C. (Verfasst von)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 19 July 2020
In: BMC cancer
Year: 2020, Jahrgang: 20
ISSN:1471-2407
DOI:10.1186/s12885-020-07100-z
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12885-020-07100-z
Volltext
Verfasserangaben:Maryam Soleimani Dodaran, Simone Borgoni, Emre Sofyalı, Pernette J. Verschure, Stefan Wiemann, Perry D. Moerland and Antoine H.C. van Kampen
Beschreibung
Zusammenfassung:Estrogen receptor (ER) positive breast cancer is often effectively treated with drugs that inhibit ER signaling, i.e., tamoxifen (TAM) and aromatase inhibitors (AIs). However, 30% of ER+ breast cancer patients develop resistance to therapy leading to tumour recurrence. Changes in the methylation profile have been implicated as one of the mechanisms through which therapy resistance develops. Therefore, we aimed to identify methylation loci associated with endocrine therapy resistance.
Beschreibung:Gesehen am 01.09.2020
Beschreibung:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-020-07100-z

Ähnliche Einträge